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INTRODUCTION
The physiopathology of insulin resistance in women with
polycystic ovary syndrome (PCOS) is related to a dis-
turbance in the function of the insulin receptor. In fact, the
post-receptor defect associated with PCOS may be a critical
factor that interferes with the recruitment of proteins for
intracellular glucose transport. The conceivable end result is
a compensatory increase in insulin (1). One possible option
for correcting this insulin resistance is the use of drugs (such
as metformin and glitazones) that may increase glucose
intake in the tissue (1,2). However, there are studies
showing that a few patients interrupted their metformin
treatment due to a high incidence of gastrointestinal side
effects, such as nausea or vomiting (2).
Rosiglitazone binds to the peroxisome proliferator-acti-
vated receptor, which regulates the transcription of many
genes, including the glucose transporter, and decreases
insulin resistance (4); however, this drug may increase the
risk of cardiovascular diseases, such as myocardial infarc-
tion. These effects are not reported in patients who have
insulin resistance without diabetes (5). It is important to
emphasize that endothelial damage is more pronounced in
diabetic patients than in non-diabetic ones (6).
Approximately 1% of IGF-1 circulates freely in the
plasma; the remainder is transported by binding proteins.
The efficacy of muscle IGF-1 depends on the expression and
availability of a family of six types of binding proteins. In
humans, the most important of these proteins is IGFBP-3
(.80%), which is responsible for the maintenance of the
circulating IGF-1 levels, along with the ALS glycoprotein,
which has great affinity for IGF-1 and -2 (7). The increase in
insulin may affect IGF-1 actions. In fact, insulin decreases
the production of IGFBP-3 in the liver. Therefore, the free
levels of IGF-1 are elevated and may affect ovarian function
and increase androgen production (8). The aim of this study
was to evaluate the actions of rosiglitazone on IGF-1 and
IGFBP-3 in women with PCOS.
MATERIALS AND METHODS
This study was conducted at the General Gynecology
Outpatient Clinic, University Hospital, Federal University
of Paraı´ba, from 2007-2008. The protocol was approved by
the Institutional Ethics and Research Committee (? 405/
2004) and Clinical Trials (PFU-IRB#405/2004). The patients
were randomly assigned to two groups: rosiglitazone and
placebo. All patients signed informed consent statements.
The PCOS diagnosis was based on the AES-2006 Criteria
(3). The exclusion criteria included the following: the use of
hormonal contraceptives; other causes of anovulation (i.e.,
Cushing’s syndrome, hyperprolactinemia, adrenal enzyme
deficiency, thyroid disorders, and adrenal or ovarian
tumors); high serum glutamic oxaloacetic transaminase
(GOT) and glutamic pyruvic transaminase (GPT) levels
(e.g., a threefold increase in the normal level); serum levels
of total cholesterol over 300 mg/dL; or triglycerides higher
than 400 mg/dL. Also excluded were users of drugs,
hormones or substances that might interfere with carbohy-
drate metabolism up to three months prior to the study or
patients who had recently started intensive physical
exercise (i.e., aerobics).
Selection of patients
The study procedures included the performance of
anamnesis and a general physical and gynecological
examination; the collection of anthropometric data (includ-
ing measurements of weight [kg], height [m], abdominal
circumference [AC, cm], hip circumference [HC, cm]), and
blood pressure with a sphygmomanometer [mmHg]; a
calculation of body mass index [BMI, weight/height2] and
waist-hip ratio [WHR, AC/HP]; and a classification of
hirsutism according to Ferriman & Gallwey (9). A patient
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was deemed hirsute if her index was over 8. All patients
were advised to use a non-hormonal contraceptive method.
Measurements were made of the following factors: follicle-
stimulating hormone, luteinizing hormone, 17 beta-estradiol,
free and total testosterone, thyroid-stimulating hormone, free
thyroxine (T4), 17 hydroxyprogesterone (17OHP), dehydroe-
piandrosterone sulfate (DHEA-S), GH, cortisol, androstene-
dione, prolactin, and serum levels of IGF-1, IGFBP-3, and
SHBG. Blood was collected to determine the lipid profiles
and the glucose and insulin levels for both treatment groups.
The participants received 75 g of saccharose, followed by
collection of another blood sample 2 hours later (10). The
following tests were also conducted: creatinine, hemogram,
and beta-human chorionic gonadotropin assays. These mea-
sures were made before and after treatment. Additionally,
blood samples were collected for FSH and LH after the third
day of the menstrual cycle from cycling patients and on any
day from patients with amenorrhea.
After interviewing patients to collect their clinical histories
and subject them to general physical and gynecological
examinations, 60 women were selected to participate. Each
patient received capsules labeled ZX or XZ and information
about the meaning of these labels. Each capsule taken by the
ZX group contained 4 mg of rosiglitazonemaleate (AvandiaH,
GlaxoSmithKline), and each capsule taken by the XZ group
contained starch (e.g., placebo, an inactive substance). Parti-
cipants were instructed to take the medication orally, twice a
day, at 12-hour intervals, during three months.
The presence of insulin resistance was determined by the
HOMA IR (11) andQUICK (11,12). TheHOMA-IRwas used to
evaluate insulin sensitivity, and values .2.7 were considered
to be indicative of insulin resistance (13).Only 33 women
completed the 12 weeks of treatment and were included in the
statistical analyses (Figure 1). We evaluated the diary card for
the days of menstruation, compliance with medication use
(e.g., the number of consumed capsules), and the side effects.
We excluded the patients who did not take at least 90% of
their medication (n=4) or who had become pregnant (n=4).
Statistical Analysis
The following tests were used for analysis Wilcoxon,
Mann-Whitney, Pearson correlations and Chi-square. The
data from the variables were organized using Excel
spreadsheets and were then converted to files using the
statistical program Statistical package for the Social Sciences
(SPSS, DMSS, www.spss.com.br), version 13.0. p-values
smaller than 0.05 were regarded as statistically significant.
RESULTS
The anthropometric data and the summaries of the
clinical data on menstrual patterns, cutaneous repercussions
of hyperandrogenism (i.e., acne), and acanthosis nigricans
(e.g., insulin resistance) are shown in Table 1. The hormonal
data and levels of serum SHBG, glucose, insulin, type 1
insulin growth factor (IGF-1), and its binding protein
(IGFBP-3) are shown in Table 2.
Figure 2 shows the linear regression data. Graphs A and B
show that the coefficient of determination (R2) of the
rosiglitazone group was greater than that of the control
group. The values of the two regression equation slopes
decreased from 0.824 to 0.765, indicating that patients in the
group treated with rosiglitazone had a significant decrease in
their HOMA-IR values. These data show that compared to
the control group, rosiglitazone significantly decreased the
HOMA-IR values. The effects of rosiglitazone on IGF-1 levels
and the HOMA-IR are represented in Figure 2 (C-F). Results
indicate that compared to the placebo group, the IGF-1 levels
decrease in parallel with the values of HOMA-IR following
rosiglitazone treatment (Fig 2, E-F, p,0.01). We did not
identify any differences in the correlations of HOMA-IR and
IGF-1 between the two groups before the treatment (C-D).
The opposite effect of rosiglitazone was observed in the
comparisons between the HOMA-IR values and the IGFPB-3
levels. Low HOMA-IR values were correlated with high
levels of IGFPB-3 after treatment (Fig 2, G-H, p,0.01). We
also did not observe any differences in the correlations of the
HOMA-IR values and the IGFPB-3 levels before treatment
across the two groups (Fig. 2 I-J).
DISCUSSION
Various drugs can be used in the treatment of PCOS,
including oral contraceptives, anti-androgens, anti-estrogens
and, more recently, insulin-sensitizing agents (i.e., bigua-
nides and thiazolidinediones) (14). The latter agents have
been used to reduce hyperinsulinemia, including its negative
impact on ovarian function and long-term cardiovascular
consequences (15). Insulin-sensitizing agents are replacing
the well-established and frequently used oral contraceptives,
which aggravate the insulin resistance and glucose intoler-
ance induced by increasing the risk of developing type 2
diabetes, elevating triglyceride levels, and raising the
cardiovascular risks, due to the oral contraceptives actions
on coagulability and vascular reactivity (16). Some authors
have suggested that such a change in carbohydrate metabo-
lism occurs in 70% of women (17). Although not all of our
patients exhibited insulin resistance, we found a correlation
between the HOMA-IR value and IGF-1 or IGFPB-3 levels.Figure 1 - Study fluxogram.
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Although the exact pathogenesis of PCOS still remains
unknown, the insulin resistance and hyperinsulinemia
appear to play key pathogenetic roles in the ovarian
overproduction of androgens (12,13). The SHBG levels
increased with therapy, further reducing the bioavailability
of circulating androgens. These changes were most likely
caused by an improvement in insulin sensitivity, resulting
in the amelioration of hyperinsulinemia and thus the
reduction of ovarian androgen production (18,19). In fact,
our study showed that rosiglitazone indeed influenced
hormone profiles, with reductions observed in both free and
total testosterone levels in women with PCOS.
The decrease in peripheral insulin resistance in PCOS
resulting from the employment of metformin and rosiglita-
zone may lead to diminished hyperinsulinemia and may
interrupt the triggering and perpetuating mechanisms of
hyperandrogenism in PCOS patients (20,21). In our study, we
identified a correlation between the amelioration of insulin
Table 2 - Hormone values, SHBG values, and glycemia, insulin, type 1 insulin-like growth factor (IGF-1), and type 3
insulin-like growth factor-binding protein (IGFBP-3) levels of the women with PCOS in both the placebo and
rosiglitazone groups (means ¡ standard deviations).
Variable
Placebo
(n=17)
Rosiglitazone
(n= 16)
Before
treatment
After
treatment p-value
Before
treatment
After
treatment p-value
FSH (mIU/mL) 5.90¡1.78 4.75¡1.55 0.023 4.75¡1.15 4.23¡1.58 0.277
LH (mIU/mL) 15.71¡16.02 10.95¡5.32 0.619 10.88¡5.37 8.72¡6.78 0.163
E2 (nmol/mL) 73.77¡81.38 75.03¡41.38 0.368 56.82¡21.49 81.94¡72.02 0.605
17OHP (mg/mL) 1.71¡0.89 1.99¡00.97 0.408 1.79¡0.90 1.45¡0.56 0.352
DHEA-S (mg/mL) 225.00¡83.60 215.68¡64.43 0.586 209.09¡60.18 179.54¡54.39* 0.026
SHBG (nmol/mL) 32.82¡15.22 30.94¡12.04 0.836 32.29¡11.61 45.18¡15.56* 0.030
T total (mg/dL) 0.78¡0.26 0.73¡0.28 0.266 0.72¡0.27 0.60¡0.27 0.570
A (ng/mL) 3.86¡1.51 4.00¡1.39 0.507 3.11¡1.18 2.15¡0.68* 0.002
T free (ng/dL) 2.91¡2.00 2.78¡1.69 0.925 2.47¡0.99 1.37¡0.57* 0.006
Glucose
(mg/dL)
80.91¡14.02 84.88¡5.64 0.179 87.94¡7.40 78.43¡13.85 0.488
Insulin
(mIU/mL)
13.20¡9.07 14.81¡8.99 0.309 13.38¡7.36 12.50¡9.46 0.379
HOMA IR 3.30¡1.92 2.82¡2.04 0.163 2.96¡1.81 2.22¡1.56 0.251
QUICK 0.33¡0.27 0.34¡0.40 0.065 0.33¡0.27 0.35¡0.33 0.379
G 2h 117.76¡31.90 95.00¡19.94 0.001 114.62¡35.59 104.31¡34.4 0.020
I 2h 103.50¡64.38 92.69¡70.31 0.535 112.98¡88.74 64.04¡64.23* 0.001
G 2h/I 2h 1.46¡0.65 1.58¡0.69 0.492 1.37¡0.58 2.30¡1.21* 0.002
IGF-1
(ng/mL)
186.24¡66.45 218.88¡70.31 0.005 196.12¡68.25 176.94¡53.31* 0.028
IGFBP-3
(ng/mL)
5.43¡0.93 5.01¡1.16 0.201 4.86¡0.82 5.34¡0.70 0.041
17OHP = 17 hydroxyprogesterone; T = testosterone; A = androstenedione. The Wilcoxon test was used for comparing the measurements made in each
group (placebo or rosiglitazone) before and after treatment. HOMA-IR and QUICK are mathematical equations for evaluating insulin resistance. G2h –
glycemia after 2 h of glycemic overload with 75 g of saccharose; I 2h – insulin after 2 h of glycemic overload with 75 g of saccharose. The Wilcoxon test
was applied for comparing the results between placebo and rosiglitazone. *p,0.05 compared to the placebo group after treatment using the Mann-
Whitney test.
Table 1 - Clinical data for the women with PCOS in the placebo and rosiglitazone groups.
Variable Placebo (n=17) Rosiglitazone (n= 16)
Baseline After treatment p-value Baseline After treatment p-value
Menstrual Pattern Oligomenorrhea
(%)
58.8 64.7 0.564 50.0 37.5 0.026
Amenorrhea (%) 41.2 35.3 50.0 0.00*
Regular (%) 0.00 0.000 0.000 0.625
Age (years) 26.29¡5.31 26.29¡5.31 1.000 24.56¡4.33 24.56¡4.33- 1.000
Weight (kg) 72.65¡15.82 72.45¡16.63 0.987 68.20¡14.39 68.15¡15.29 0.983
BMI (kg/m2) 30.09¡6.51 30.19¡7.42 0.976 27.89¡6.10 27.79¡7.20 0.972
WHR 0.87¡0.12 0.86¡0.22 0.950 0.88¡0.86 0.87¡0.75 0.970
Height (m) 1.55¡0.05 1.55¡0.05 1.000 1.56¡0.06 1.56¡0.06 1.000
Ferriman-Gallwey
index
9.76¡4.92 - 8.81¡3.76 -
Acne (%) 35.3 29.4 0.317 37.5 6.3* 0.025
AN (%) 47.1 47.1 1.000 48.3 12.5* 0.045
The data are summarized as means¡ standard deviations in both groups (n) = Number of women. Acronyms: BMI = body mass index, WHR = waist hip
ratio, AN = acanthosis nigricans. Hirsutism reported by the patients. The results for menstrual cycle pattern, acne, hirsutism, and AN were analyzed using the
chi-square test. The Wilcoxon test was applied for comparing the results between placebo and rosiglitazone. *p, 0.05 compared to the placebo group.
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resistance and decreased IFG-1 and IFGBP-3 levels. We also
observed a decrease in the free testosterone fraction and an
increase in SHBG. Hirsutism was not evaluated in this study
because the hair follicle cycle ranges from six months to two
years (6,22), thus requiring a more prolonged treatment to
observe any changes than was possible in the time frame of
Figure 2 - Pearson’s correlation between insulin resistance and IGF-1 and IGFPB-3. A – Correlation of HOMA-IR values before vs. after
treatment in the control group; B - Correlation of HOMA-IR values before vs. after treatment in the rosiglitazone group; C – Correlation
of HOMA-IR values with IGF-1 levels before treatment in the control group; D - Correlation of HOMA-IR and IGF-1 levels before
treatment in the rosiglitazone group; E - Correlation of HOMA-IR values with IGF-1 levels after treatment in the control group;
F - Correlation of HOMA-IR values with IGF-1 levels after treatment in the rosiglitazone group; G - Correlation of HOMA-IR values with
IGFPB-3 levels before treatment in the control group; H - Correlation of HOMA-IR values with IGFPB-3 levels before treatment in the
rosiglitazone group; I - Correlation of HOMA-IR values with IGFPB-3 levels after treatment in the control group; J - Correlation of
HOMA-IR values with IGFPB-3 levels after treatment in the rosiglitazone group.
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this study. However, acne, which is also dependent on
hyperandrogenism, improved in our patients (23).
There was a post-treatment reduction in the IGF-1 levels
in the women who took rosiglitazone. This result is
controversial in the literature. In patients with acromegaly
(a disease that raises GH and IGF-1 levels), rosiglitazone did
not reduce IGF-1 or its binding proteins (24,25). There was,
however, a decrease in these factors in patients with both
acromegaly and diabetes mellitus (26,27). In fact, insulin
may diminish IGF-1 and its binding proteins at the hepatic
level, thus limiting the effects of IGF-1 and, therefore,
ovarian stimulation (28).
Our results demonstrated that rosiglitazone might
improve hyperandrogenism and insulin resistance in
PCOS women. These beneficial effects were observed with
the three-month treatment. It is also relevant that the
menstrual patterns normalized during this interval of
observation.
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